Developmental Toxicology, Drugs, and Fetal Teratogenesis

Clinical Obstetrics. The Fetus & Mother: Third Edition

Volumn , Issue , 2008, Pages 215-235

  Brent, Robert L ^a   Fawcett, Lynda B ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Congenital malformations; Environmental agents; Fetal teratogenesis; Hereditary diseases; Pharmacokinetics

Indexed keywords

EID: 84891985726     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470753293.ch15     Document Type: Chapter

References (74)

1. Brent RL. Medicolegal aspects of teratology. J Pediatr 1967;71: 288-298.
2. Brent RL. Litigation-produced pain, disease and suffering: an experience with congenital malformation lawsuits. Teratology 1977; 16:1-14.
3. Brent RL. Utilization of developmental basic science principles in the evaluation of reproductive risks from pre-and postconception environmental radiation exposures. Teratology 1999;59:182-204.
4. Brent RL, Holmes L. Clinical and basic science lessons from the thalidomide tragedy: what have we learned about the causes of limb defects? Teratology 1988;38:241-251.
5. Brent RL. The irresponsible expert witness: a failure of biomedical graduate education and professional accountability. Pediatrics 1982;70:754-762.
6. Brent RL. Drugs and pregnancy: are the insert warnings too dire? Contemp Ob-Gyn 1982;20:42-49.
7. Wilson J. Environment and birth defects. New York: Academic Press, 1973.
8. Brent RL. Environmental factors: miscellaneous. In: Brent RL, Harris M, eds. Prevention of embryonic, fetal and perinatal disease. Bethesda, MD: John E. Fogarty International Center for Aduanced Study in the Health Sciences, NIH; 1976:211.
9. Heinonen O, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group, 1977.
10. Brent RL, Beckman D. Environmental teratogens. New York: New York Academy of Medicine, 1990.
11. Beckman D, Fawcett L, Brent RL. Developmental toxicity. In: Massaro E, ed. Handbook of human toxicology. New York: CRC Press; 1997:1007-1084.
12. Brent RL, Beckman D. Prescribed drugs, therapeutic agents, and fetal teratogenesis. In: Reece E, Hobbins J, eds. Medicine of the fetus and mother, 2nd edn. Philadelphia, PA: Lippincott-Raven Publishers; 1999:289-313.
13. Aase J. Diagnostic dysmorphology. New York: Plenum Medical Book Co., 1990.
14. Beckman D, Brent RL. Fetal effects of prescribed and self-administered drugs during the second and third trimester. In: Avery G, Fletcher M, MacDonald M, eds. Neonatology: patho-physiology and treatment, 4th edn. Philadelphia, PA: JB Lippincott Co.; 1994:197-206.
15. Brent RL. What is the relationship between birth defects and pregnancy bleeding? New perspectives provided by the NICHD workshop dealing with the association of chorionic villous sampling and the occurrence of limb reduction defects. Teratology 1993;48: 93-95.
16. Brent RL, Beckman D. Teratogens: an overview. In: Knobil E, Neill J, eds. Encyclopedia of reproduction. New York: Academic Press; 1999:735-750.
17. Graham JJ, Jones K, Brent RL. Contribution of clinical teratolo-gists and geneticists to the evaluation of the etiology of congenital malformations alleged to be caused by environmental agents, ionizing radiation, electromagnetic fields, microwaves, radionuclides, and ultrasound. Teratology 1999;59:307-313.
18. Jones K. Smith's recognizable pattern of human malformations, 5th edn. Philadelphia, PA: WB Saunders Co., 1994.
19. Brent RL, Beckman D. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical teratology councilors. Teratology 1991;43:543-545.
20. Brent RL. Methods of evaluating the alleged teratogenicity of environmental agents. In: Sever J, Brent RL, eds. Teratogen update: environmentally induced birth defect risks. New York: Alan R Liss; 1986:199-201.
21. Brent RL. Effects and risks of medically administered isotopes to the developing embryo. In: Fabro S, Scialli A, eds. Drug and chemical action in pregnancy. New York: Marcel Dekker; 1986:427439.
22. Brent RL. Radiation teratogenesis. Teratology 1980;21:281-298.
23. Brent RL, Beckman D. Developmental effects following radiation of embryonic and fetal exposure to x-ray and isotopes: counseling the pregnant and nonpregnant patient about these risks. In: Hendee W, Edwards F, eds. Health effects of low levels exposure to ionizing radiation. Bristol & Philadelphia: Institute of Physics Publishing; 1996:169-213.
24. Online Mendelian Inheritance in Man, OMIM™. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), 2000. World Wide Web URL:http://www.ncbi.nlm.nih.gov/omim/
25. Brent RL. Evaluating the alleged teratogenicity of environmental agents. In: Brent RL, Beckman D, eds. Clinics in perinatology. Philadelphia, PA: WB Saunders; 1986:609-613.
26. Brent RL. Protecting the public from teratogenic and mutagenic hazards. J Clin Pharmacol 1972;12:61-70.
27. Brent RL. Drug testing in animals for teratogenic effects: thalidomide in the pregnant rat. J Pediatr 1964;64:762-770.
28. Brent RL. The prediction of human diseases from laboratory and animal tests for teratogenicity, carcinogenicity, and mutagenicity. In: Lasagna L, ed. Controversies in therapeutics. Philadelphia, PA: WB Saunders; 1980:134-150.
29. Brent RL. Predicting teratogenic and reproductive risks in humans from exposure to various environmental agents using in vitro techniques and in vivo animal studies. Cong Anomalies 1988; 28(Suppl.):41-55.
30. Christian M, Brent RL. Teratogen update: evaluation of the reproductive and developmental risks of caffeine. Teratology 2001;64: 51-78.
31. Brent RL. Scientific frontiers in developmental toxicology and risk assessment (Review). Teratology 2002;65:88-96.
32. Brent RL. Teratogen update: reproductive risks of leflunomide (Avara). A parimidine synthesis inhibitor: counseling women lacking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology 2001;63:106-112.
33. Carter C. Genetics of common single malformations. Br Med Bull 1976;32:21-26.
34. Fraser F. The multifactorial/threshold concept: uses and misuses. Teratology 1976;14:267-280.
35. Boue J, Boue A, Lazar P. Retrospective and prospective epidemi-ological studies of 1500 karyotyped spontaneous abortions. Teratology 1975;12:11-26.
36. Hertig A. The overall problem in man. In: Benirschke K, ed. Comparative aspects of reproductive failure. Berlin: Springer-Verlag; 1967:11.
37. Simpson J. Genes, chromosomes and reproductive failure. Fertil Steril 1980;33:107-116.
38. Sever J. Infections in pregnancy: highlights from the collective perinatal project. Teratology 1982;25:227-237.
39. Briggs M, Briggs M. Sex hormone exposure during pregnancy and malformations. Adv Steroid Biochem Pharmacol 1979;7:51-89.
40. Hochner-Celnikier D, Marandici A, Iohan F, Monder C. Estrogen and progesterone receptors in the organs of prenatal Cynomolgus monkey and laboratory mouse. Biol Reprod 1986;35:633-640.
41. Wilson J, Brent RL. Are female sex hormones teratogenic? Am J Obstet Gynecol 1981;141:567-580.
42. Jackson M. Drug absorption. In: Fabro S, Scialli A, eds. Drug and chemical action in pregnancy: pharmacologic and toxicologic principles. New York: Marcel Dekker; 1986:15.
43. Mattison D. Physiologic variations in pharmacokinetics during pregnancy. In: Fabro S, Scialli A, eds. Drug and chemical action during pregnancy: pharmacologic and toxicologic principles. New York: Marcel Dekker; 1986:37-102.
44. Sonawane B, Yaffe S. Physiologic disposition of drugs in the fetus and newborn. In: Fabro S, Scialli A, eds. Drug and chemical action in pregnancy: pharmacologic and toxicologic principles. New York: Marcel Dekker; 1986:103.
45. Juchau M, Rettie A. The metabolic role of the placenta. In: Fabro S, Scialli A, eds. Drug and chemical action in pregnancy: phar-macologic and toxicologic principles. New York: Marcel Dekker; 1986:153-169.
46. Yang H, Namkung M, Juchau M. Cytochrome P450-dependent biotransformation of a series of phenoxazone ethers in the rat con-ceptus during early organogenesis: evidence for multiple P450 isozymes. Mol Pharmacol 1988;34:67-73.
47. Fantel A, Person R, Juchau M. Niridazole metabolism by rat embryos in vitro. Teratology 1988;37:213-221.
48. Juchau M. Bioactivation in chemical teratogenesis. Annu Rev Pharmacol Toxicol 1989;29:165-187.
49. Miller R. Placental transfer and function: the interface for drugs and chemicals in the conceptus. In: Fabro S, Scialli A, eds. Drug and chemical action in pregnancy: pharmacologic and toxicologic principles. New York: Marcel Dekker; 1986:123.
50. Mirkin B. Maternal and fetal distribution of drugs in pregnancy. Clin Pharmacol Ther 1973;14:643-647.
51. McKusic V. Medelian inheritance in man: catalogs of autosomal dominant, autosomal recessive, and x-linked phenotypes, 8th edn. Baltimore, MD: Johns Hopkins University Press, 1988.
52. Brent RL. Bendectin: review of the medical literature of a comprehensively studied human non-teratogen and the most prevalent tortigen-litigen. Reprod Toxicol 1995;9:337-349.
53. Brent RL. Review of the scientific literature pertaining to the reproductive toxicity of bendectin. In: Faigman D, Kaye D, Saks M, et al., eds. Modern scientific evidence: the law and science of expert testimony. St. Paul, MN: West Publishing Group; 1997: 373.
54. Brent RL. Microwaves and ultrasound. In: Queenan J, Hobbins J, eds. Protocols for high risk pregnancies, 3rd edn. Cambridge: Blackwell Scientific; 1995:37-43.
55. Brent RL, Gordon W, Bennett W, Beckman D. Reproductive and teratogenic effects of electromagnetic fields. Reprod Toxicol 1993;7:535-580.
56. Friedman J, Polifka J. ERIS. The teratogen information system. Seattle, WA: University of Washington, 1999.
57. Scialli A, Lione A, Padget GKB. Reproductive effects of chemical, physical and biologic agents. Baltimore, MD: Johns Hopkins University Press, 1995.
58. Sever J, Brent RL. Teratogen update: environmentally induced birth defect risks. New York: Alan R Liss, 1986.
59. Sheperd T. Catalogue of teratogenic agents, 8th edn. Baltimore, MD: Johns Hopkins University Press, 1995.
60. Schardein J. Chemically induced birth defects. New York: Marcel Dekker, 1993.
61. Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation, 3rd edn. Baltimore, MD: Williams and Wilkins, 1990.
62. Miller R. How environmental hazards have been discovered: carcinogens, teratogens, neurotoxins, and others. Pediatrics 2004; 113:945-951.
63. Physicians Desk Reference, 57th edn: Medical Economics Co. Montvale, NJ: Thomson Healthcare; 2003.
64. Friedman J, Little B, Brent RL, et al. Potential human terato-genicity of frequently prescribed drugs. Obstet Gynecol 1990;75: 594-599.
65. Dam K, Seidler F, Slotkin T. Transcriptional biomarkers distinguish between vulnerable periods for developmental neurotoxic-ity of chlorpyrifos: implications for toxicogenomics. Brain Res Bull 2003;59:261-265.
66. Tyl R, Myers C, Thomas B, et al. Three-generation reproductive toxicity study of dietary bisphenol A in CD Sprague-Dawley rats. Toxicol Sci 2002;68:121-146.
67. Yamada H, Furuta I, Kato E, et al. Maternal serum and amniotic fluid bisphenol A concentrations in the early second trimester. Reprod Toxicol 2002;16:735-739.
68. Holson J, DeSesso J, Jacobson C, Farr C. Appropriate use of animal models in the assessment of risk during prenatal development: an illustration using inorganic arsenic. Teratology 2000;62:51-71.
69. Brent RL, Jensh R, Beckman D. Medical sonography: reproductive effects and risks. Teratology 1991;44:123-146.
70. Wilson J, Brent RL, Jordan H. Differentiation as a determinant of the reaction of rat embryos to x-irradiation. Proc Soc Exp Biol Med 1953;82:67-70.
71. Brent RL. Commentary on bendectin and birth defects: hopefully the final chapter. Birth Defects Res 2003;67:79-87.
72. Roberts C, Lowe C. There have all the conceptions gone? Lancet 1975;1:498-499.
73. Brent RL. Editorial: definition of a teratogen and the relationship of teratogenicity to carcinogenicity. Teratology 1986;34:359-360.
74. Brent RL. Method of evaluating alleged human teratogens. Teratology 1978;17:83.